Bajaj Healthcare Limited reported a steep decline in its financials for the last quarter of the fiscal year ending March 2026, turning to a standalone net loss of ₹22.85 crore. This is a steep reversal from a profit of Rs 11.17 crore in the same period last year. The company’s operational revenue remained largely flat at ₹153.05 crore, a marginal dip of less than 1% YoY. The bottomline was hit hard by a one-time exceptional item.
The main reason for this “dismal” performance was an income reversal of ₹33.2 crore on account of cancellation of a technical know how arrangement in the middle east owing to instability in the region. Apart from the one-time charge, the company also had to contend with significant headwinds from pricing pressures in the domestic Active Pharmaceutical Ingredients (API) market and increasing raw material costs. The cost of a key input, Isopropyl Alcohol, jumped significantly recently, squeezing margins further.
Earlier this year, management cited an 18% rise in nine-month revenue and recommended a final dividend of ₹1.50 per share, indicating some confidence about long-term liquidity even as the company reported a quarterly setback. But the market is wary as the company slips into negative territory from a profit margin of 7.2% a year ago. Looking ahead, investors are keenly waiting for the new production lines at the Savli facility to be commissioned and the acquisition of Genrx Pharmaceuticals to be completed to see if the strategic initiatives will aid a return to profitability in the next fiscal year.